0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

SUDDEN DEATH FOLLOWING INTRAVENOUS ADMINISTRATION OF "DIODRAST"

SAMUEL SIMON, M.D.
JAMA. 1948;138(2):127-128. doi:10.1001/jama.1948.62900020002007a.
Text Size: A A A
Published online

The basis for this report is a fatality subsequent to the intravenous administration of iodopyracet injection ("diodrast"). The incidence of such fatalities is rare. Pendergrass and his co-workers,1 in 1942, following a fatal reaction to iodopyracet injection at the University of Pennsylvania, made a survey of this diagnostic procedure throughout the United States and Canada. They sent out three thousand questionnaires to radiologists and urologists and received a report on 661,800 urographic examinations. In analyzing these reports, they encountered twenty-six unreported fatal reactions to iodopyracet injection in addition to eleven fatalities that had been reported in the literature up to that time. This represented an incidence of one fatality to twenty-five thousand injections. They reported two types of deaths: (1) immediate, due to allergy to the drug, and (2) delayed, due to preexisting major renal damage. Eleven of twenty-six deaths were immediate deaths, occurring in an average time of

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();